A new report has highlighted a growing concern within the Scottish hospitality sector, suggesting that the widespread use of weight-loss drugs, such as Ozempic and Wegovy, is contributing to a decline in business for pubs and restaurants. The analysis points to a change in consumer behavior, where individuals taking these medications may be experiencing reduced appetites or a diminished desire for alcohol, leading to lower spending at dining and drinking establishments.

While the report identifies a correlation between the surge in pharmaceutical weight-loss solutions and reduced foot traffic in hospitality venues, it does not provide definitive data on the long-term economic impact. Industry representatives have expressed concern that if these trends continue, businesses may need to adapt their offerings to cater to a demographic that is increasingly prioritizing health-conscious choices over traditional pub fare. Conversely, some health advocates argue that the focus should remain on the medical benefits of these treatments rather than the financial performance of the hospitality industry. As the popularity of these drugs continues to rise, the debate highlights a tension between public health outcomes and the traditional business models of the food and beverage sector.